GemPharmatech

A New Way to Explore Preclinical Research Solutions Finding the right model, preclinical strategy, and scientific information is critical for successful drug discovery. The redesigned GemPharmatech website brings together our comprehensive mouse model portfolio, integrated preclinical research capabilities, and scientific resources—helping researchers discover solutions more efficiently.

#Neutrophils are known as the body’s first responders and co-ordinators of immune defense. But do they play a more malignant role in #cancer progression? Recent discoveries reveal that immature neutrophils do not just accumulate in primary and metastatic tumors. They also actively suppress anti-tumor immunity, limiting the effectiveness of immunotherapies. GemPharmatech is proud to host 𝗣𝗿𝗼𝗳𝗲𝘀𝘀𝗼𝗿 𝗬𝗮𝗻 𝗟𝗶, 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿 𝗼𝗳 𝗡𝗮𝗻𝗷𝗶𝗻𝗴 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗶𝘁𝘆’𝘀 𝗠𝗼𝗱𝗲𝗹 𝗔𝗻𝗶𝗺𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗖𝗲𝗻𝘁𝗲𝗿, who will present groundbreaking research on how distinct immature neutrophil subsets fuel #tumor growth and metastasis, and how novel therapeutic strategies can restore immunity and enhance checkpoint inhibitor response. Key topics include: ✔️ Neutrophil Heterogeneity in Cancer: dominance of immature subsets in primary and metastatic tumors. ✔️ Mechanisms of Immune Suppression: CD63/Galectin-3+ neutrophils in primary tumors and Ckap4+ subsets in bone metastases. ✔️ Therapeutic Interventions: Flt3L-induced trans-differentiation and DKK1 blockade to restore T-cell function and enhance checkpoint inhibitor therapy. ✔️ Next-generation Models: human immune system (HIS) mouse models with peripheral human neutrophil engraftment. Register now to reserve your spot: https://lnkd.in/dsKXZYmv Learn more: https://lnkd.in/dX5CtrkH #Webinar #GemPharmatech #MouseModels #WebinarAlert #GEMMs #Innovation #Research #Biotech #RegistrationOpen #CancerResearch #Immunotherapy #Immunesystem #Antitumor #Oncology #TumorMicroenvironment #CheckpointInhibitors #MedicalResearch #Tumorgrowth #Tumormetastasis

Report on R&D trends and breakthrough innovations for #neurological diseases is out now! Despite immense progress, the path from discovery to deployment remains arduous for therapeutic developers. As new therapeutic research expands into biologics, gene therapies, and cell-based interventions, clinically relevant models that generate reliable, reproducible, and translatable data are essential. Our recent collaboration with Inpart covers the latest R&D trends and breakthrough innovations, including a spotlight on our next-generation neuroscience platform to the early-stage research community. Check out the report for key insights into the neurological R&D landscape and the highest-impact early-stage breakthroughs, ranked by industry engagement. 📥 Download the Report Now: https://lnkd.in/gSpG-s_C #Neuroscience #Neurology #DrugDiscovery #Biotech #GeneTherapy #CellTherapy #TranslationalResearch #AlzheimersDisease #GemPharmatech

Learn about latest in vivo offerings.

Keep up with interesting, relevant updates

🚀 Advance your ADC pipeline with more predictive models. Register now: https://lnkd.in/gC75S8vC The models: ✅ A HER2-positive JIMT-1 breast cancer CDX model with acquired resistance to Enhertu ✅ A primary resistant HER2-positive lung cancer PDX model from our patient-derived xenograft (PDX) library GemPharmatech's oncology expert will also cover: 🔹 Uncovering resistance mechanisms 🔹 Improving preclinical predictability 🔹 Evaluation next-generation ADC strategies #CancerTherapy #CancerResearch #Oncology #PreclinicalModels #GemPharmatech